diagnost tool
addit newer pivot launch clinic diagnost assay breast
cancer htg togeth partner hope advanc assay develop
autoimmun cardiovascular diseas fibrosi disord htg deliv modest
beat reiter full year guid meanwhil learn within next
quarter fate program like determin whether
htg hit high low end guid reiter price target
beat rev y/i beat guid
htg core product revenu beat off-set
research revenu y/i two activ pdp
program hold paus recal collabor revenu lumpi
htg drove growth pharma pdp revenu lp beat
lighter spend htg hold cash balanc sheet
amend april htg amend ivd test develop agreement
develop commerci rna dna profil test
use ilmn miseqdx sequenc oncolog diagnost updat agreement
may extend autoimmun diseas cardiovascular diseas fibrosi
diseas htg plan enter auto-immun market launch gene
express liquid biopsi auto-immun panel later
pdp updat htg reiter revenu guid visibl time
pdp mileston limit htg expect hear decis soon
think could hit within next quarter two htg engag
manag highest level lack visibl outcom time
recent hire bay area offic suggest pivot dx recent month htg hire dr
maureen cronin formerli genom health celgen foundat medicin
chief scienc offic laura beggrow presid diagnost laura held role
vice-president sale market ghdx consult color genom
share expertis breast cancer dx earli april htg launch dx develop
center san carlo ca initi develop comprehens breast
assay expect updat us assay august
billion pipelin htg current activ project biopharma pipelin
last quarter due project time project paus
year despit step-down htg reiter goal exit activ
project htg perform thorough review probability-weight valuat
pipelin size billion valu spread across wide rang cancer
exclud non-oncolog applic ie autoimmun diseas
model reiter revenu estim y/i vs htgm guid
y/i reiter revenu y/i
model valuat present exclud opportun compani may realiz beyond
think like includ companion diagnost novel diagnost
time given believ estim achiev conserv
price close busi may
htg global diagnost compani decentr
rna molecular profil proprietari
platform edgeseq pursu multipl ngs-
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
amend agreement extend beyond oncolog htg april amend
ivd test develop suppli agreement involv
develop commerci nuclease-protection-bas rna dna
profil test use ilmn miseqdx sequenc oncolog diagnost
updat agreement extend beyond oncolog includ diagnost test
autoimmun disord diseas cardiovascular disord diseas
fibrosi disord diseas htg plan enter auto-immun market launch
liquid biopsi auto-immun panel later research-us
reiter guid htg reiter revenu guid
y/i driven growth ruo profil revenue segment partial
off-set unpredictable/vari pdp collabor rev think push-out
pdp program would make difficult htg hit high end guid
announc go decis sooner rather later one two program
could push htg high end guid
pt pt use multipl revenu estim
discount back year discount rate use share count
dilut share outstand note model exclud potenti companion
diagnost hope hit lack visibl time size
new ceo announc earlier year tj johnson serv htg ceo
year move role chairman john lubniewski formerli htg presid
cbo promot ceo role known john sinc htg ipo
believ capabl compet execut much familiar htg growth
initi custom base etc like tj john ex-ventana medic execut
edgeseq reveal htg roll edgeseq reveal new softwar product use
analyz htg edgeseq precis immuno-oncolog panel data htg assert
product help enabl applic like monitor immunotherapi respons
biomark immunophenotyp applic use determin diseas
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
diagnost tool
